Hong Kong
November 7, 2024

Dr. Michael Chen, Co-founder and CEO of Great Bay Bio, and Dr. Yan Zhang, Co-founder and COO of MEGAROBO, signed the strategic cooperation agreement

Great Bay Bio (hereinafter referred to as “GBB”) and Beijing MEGAROBO Co., Ltd. (hereinafter referred to as “MEGAROBO”) signed a strategic cooperation agreement, focusing on innovative drug development in multiple major disease areas. By combining strengths, the two parties will integrate AI and automation solutions to advance critical steps in early-stage biopharmaceutical research and upstream process development. This collaboration aims to provide innovative solutions for large-molecule drugs, revolutionizing and accelerating the drug development processes.

Dr. Michael Chen, Co-founder and CEO of Great Bay Bio, stated: "MEGAROBO is committed to empowering innovation and digital transformation across various fields through the deep integration of robotics, automation, and AI with industry applications. MEGAROBO has already demonstrated outstanding innovation in life sciences, new drug development, and other areas. Through this strategic partnership, Great Bay Bio will leverage MEGAROBO's advanced productivity tools and services to further enhance intelligent biopharmaceutical development ecosystem, achieving a closed loop. This will enable intelligent drug discovery, automated drug production, and continuous support for drug discovery and CMC development, leading to cost reduction, efficiency improvement, and faster, better product development for clients."

Dr. Yan Zhang, Co-founder and COO of MEGAROBO, stated: “We are pleased to partner with Great Bay Bio to embark on deep collaboration in the field of antibody drugs, which is full of challenges and opportunities. MEGAROBO has always adhered to the vision of 'Empowering Digital Transformation with Advanced Production Tools to Make the World Healthier and Better' and is committed to applying cutting-edge technologies such as AI and automation to the core drug development processes. We believe that through our joint efforts, we can break the bottlenecks of traditional R&D models, accelerate the progress of biologics from the lab to the market, and contribute to the health and well-being of humanity."

Dr. Yan Zhang, Co-founder and COO of MEGAROBO

About Great Bay Bio：

Great Bay Bio (GBB), based in Hong Kong, is an innovative biotech company with a vision of Global Bioprocessing Made Simpler and More Efficient. Committed to utilizing AI and other cutting-edge technologies, GBB aims to address the challenges of long timelines, high costs, and low success rates in drug development, and in industries involving bioprocessing, e.g., synthetic biology, IVD and CGT. Led by a team of experienced professionals in biopharmaceuticals and AI, GBB's members boast over 20 successful IND filings approved by both China and the United States.

About MEGAROBO:

Founded in 2016, MEGAROBO is a science and technology company specializing in providing advanced production tools for life sciences, new drug discovery, clinical diagnostics, applied chemistry, and advanced manufacturing industries. MEGAROBO is dedicated to leveraging robotic automation and AI technologies to empower innovation breakthroughs and digital transformation, to engineer a more efficient, healthier, and better world.

MEGAROBO provides innovative intelligent automation products and solutions of high quality for the life sciences industry, covering R&D, production, and detection. With the research capabilities of MegaLab, the self-developed intelligent biological laboratory, MEGAROBO provides high-value productivity tools and services, accelerating the intelligent automation revolution in new drug discovery, cell and gene therapy, organoids, and synthetic biology, ultimately improving human health.